Timp-2 as target/marker of beta cell failure

• US 20100009462A1
• Filed: 07/19/2005
• Published: 01/14/2010
• Est. Priority Date: 07/28/2004
• Status: Abandoned Application

• Current Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Original Assignee: Hoffmann-La Roche Incorporated (Roche Holding AG)
• Inventors: Evers, Stefan, Sebokova, Elena, Krapfenbauer, Kurt, Christ, Andreas
• Application Number:
  US11/658,517
• Publication Number:
  US 20100009462A1
• Time in Patent Office: Days
• US Class Current: 436/501
• CPC Class Codes: G01N 2333/8146 Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
• CPC Class Codes: G01N 2500/04 Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
• CPC Class Codes: G01N 2800/042 Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

The present invention relates to the monitoring of disease progression and diagnosis of beta-cell failure in diabetes by measuring levels of TIMP-2 in a liquid sample, and to screening for novel compounds for the prevention and/or treatment of diabetes.

Claims

1. A method of screening for a compound which interacts with TIMP-2, comprising the steps of

a) contacting protein TIMP-2 with a compound or a plurality of compounds under conditions which allow interaction of said compound or a plurality of compounds with TIMP-2;

and

b) detecting the interaction between said compound or plurality of compounds with said polypeptide.

3. The method of claim 1, additionally comprising the step of immobilizing protein TIMP-2 prior to step a) or between steps a) and b).

2. A method of screening for a compound that inhibits beta cell failure, comprising the steps of

a) contacting a compound with protein TIMP-2;

b) measuring the activity of protein TIMP2

wherein a compound which inhibits the activity of protein TIMP-2 is a compound that inhibits beta cell failure.

25. The method of claim 2, additionally comprising the step of immobilizing protein TIMP-2 prior to step a) or between steps a) and b).

4. (canceled)

5. (canceled)

6. (canceled)

7. A method for monitoring the efficacy of treatment of, or monitoring the progression of, diabetes, comprising the steps of

a) providing a liquid sample obtained from a patient treated against diabetes,

b) contacting said sample with a specific binding agent for TIMP-2 under conditions appropriate for formation of a complex between said binding agent and TIMP-2, and

c) correlating the amount of complex formed in (b) to the amount of complex formed in the absence of treatment.

12. The methods of claim 7, wherein said sample is selected from the group consisting of serum, plasma and whole blood.

8. (canceled)

9. A method for monitoring the progression of, or efficacy of treatment of, diabetes, comprising the steps of

a) providing a liquid sample obtained from a patient treated against diabetes,

b) determining the activity of TIMP-2 in said sample;

c) correlating the activity of TIMP-2 in b) to the activity of TIMP-2 in the absence of treatment.

13. The method of claim 9, wherein said sample is selected from the group consisting of serum, plasma and whole blood.

10. (canceled)

11. (canceled)

14. (canceled)

15. (canceled)

16. (canceled)

17. (canceled)

18. (canceled)

19. (canceled)

20. (canceled)

21. (canceled)

22. (canceled)

23. A method for the diagnosis of beta-cell failure comprising the use of protein TIMP-2 as a marker molecule in combination with at least one other marker molecule.

24. (canceled)